SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 989-996. Prepublished online as a Blood First Edition Paper on September 18, 2007; DOI 10.1182/blood-2007-06-096594. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-06-096594v1 111/3/989    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Syrjala, K. L. Articles by Heiman, J. R. PubMed PubMed Citation Articles by Syrjala, K. L. Articles by Heiman, J. R. Related Collections Transplantation Free Research Articles Plenary Papers Clinical Trials and Observations Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PLENARY PAPER Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years Karen L. Syrjala1,2, Brenda F. Kurland1, Janet R. Abrams1, Jean E. Sanders1,3, and Julia R. Heiman2,4,6 1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 2 Department of Psychiatry and Behavioral Sciences and 3 Department of Medicine and Pediatrics, University of Washington School of Medicine, Seattle; 4 Kinsey Institute for Research in Sex, Gender, and Reproduction, 5 Department of Psychological and Brain Sciences, and 6 Department of Clinical Psychiatry, Indiana University, Bloomington This prospective study evaluated sexual function through 5 years after myeloablative allogeneic hematopoietic cell transplantation (HCT) for cancer to determine sexual function recovery and residual problems. Adults completed measures before HCT (N = 161), with survivors followed at 6 months and at 1, 2, 3, and 5 years. At 5 years case-matched controls also completed assessments. Analyses indicated that men and women differed in rates of being sexually active across time (P < .001) and in overall sexual function (P < .001). Both sexes declined in sexual activity rates and sexual function from before HCT to 6 months afterward (P .05). Activity rates recovered for men by 1 year (74%) and for women by 2 years (55%). Men improved from their 6-month nadir in sexual function by 2 years (P = .02), whereas women did not improve by 5 years (P = .17). Both male and female survivors were below controls in rates of sexual activity and sexual function at 5 years. Most women reported sexual problems (80% of survivors vs 61% of controls, P = .11); in contrast for men 46% of survivors versus 21% of controls (P = .05) reported problems. Thus, despite some recovery, sexual dysfunction remained a major problem for men and women after HCT. Aggressive efforts are needed to treat these deficits. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Sexuality in long-term survivors Gerard Socié Blood 2008 111: 972-973. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020